V. Murphy

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

A. So, N. Schlesinger, U. Arulmani, 2010, Arthritis and rheumatism.

Saturday, June 26, 2010: Free Communications

M. Inaba, Y. Nishizawa, M. Okamura, 2010, NDT plus.

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

H. Schumacher, A. So, R. Alten, 2012, Annals of the rheumatic diseases.

Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti‐inflammatory drugs early after the initiation of treatment – findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial

D. Richard, G. Krammer, R. Rebuli, 2008, Alimentary pharmacology & therapeutics.

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

A. So, N. Schlesinger, U. Arulmani, 2011, Arthritis Research & Therapy.